Supplementation of N-3 LCPUFA to the diet of children older than 2 years

A commentary by the ESPGHAN committee on nutrition

Carlo Agostoni, Christian Braegger, T. Decsi, Sanja Kolacek, Walter Mihatsch, Luis A. Moreno, John Puntis, Raanan Shamir, Hania Szajewska, Dominique Turck, Johannes Van Goudoever

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The aim of this commentary is to review data on the effect of supplementation of paediatric patients ages 2 years or older with n-3 long-chain polyunsaturated fatty acids (LCPUFA). Some evidence for a positive effect on functional outcome in children with attention-deficit/hyperactivity disorder (ADHD) was found; however, benefit was seen in only about half of the randomised controlled trials (RCT), and studies varied widely not only in dose and form of supplementation but also in the functional outcome parameter tested. The committee concludes that there are insufficient data to recommend n-3 LCPUFA supplementation in the treatment of children with ADHD, but further research on n-3 LCPUFA supplementation in ADHD may be worthwhile. The committee was unable to find evidence of a favourable effect of n-3 LCPUFA supplementation on cognitive function in children. Although no benefit of n-3 LCPUFA supplementation was seen for major clinical outcome parameters in children with cystic fibrosis, a potentially beneficial shift towards less-inflammatory eicosanoid profiles seen in 2 studies provides grounds for further investigation; it is possible that earlier and longer supplementation periods may be needed to demonstrate clinical effect. For children with phenylketonuria, the limited data available suggest that supplementation of n-3 LCPUFA to the diet is both feasible and safe, but offers only transient benefit in visual function. For children with bronchial asthma there are insufficient data to suggest that LCPUFA supplementation has a beneficial effect. The committee advises paediatricians that most health claims about supplementation of n-3 LCPUFA in various diseases in children and adolescents are not supported by convincing scientific data.

Original languageEnglish
Pages (from-to)2-10
Number of pages9
JournalJournal of Pediatric Gastroenterology and Nutrition
Volume53
Issue number1
DOIs
Publication statusPublished - Jul 2011

Fingerprint

Unsaturated Fatty Acids
Diet
Attention Deficit Disorder with Hyperactivity
Phenylketonurias
Eicosanoids
Cystic Fibrosis
Cognition
Asthma
Randomized Controlled Trials
Pediatrics
Health
Research

Keywords

  • attention-deficit/hyperactivity disorder
  • commentary
  • cystic fibrosis
  • n-3 long-chain polyunsaturated fatty acids
  • phenylketonuria

ASJC Scopus subject areas

  • Gastroenterology
  • Pediatrics, Perinatology, and Child Health

Cite this

Supplementation of N-3 LCPUFA to the diet of children older than 2 years : A commentary by the ESPGHAN committee on nutrition. / Agostoni, Carlo; Braegger, Christian; Decsi, T.; Kolacek, Sanja; Mihatsch, Walter; Moreno, Luis A.; Puntis, John; Shamir, Raanan; Szajewska, Hania; Turck, Dominique; Van Goudoever, Johannes.

In: Journal of Pediatric Gastroenterology and Nutrition, Vol. 53, No. 1, 07.2011, p. 2-10.

Research output: Contribution to journalArticle

Agostoni, C, Braegger, C, Decsi, T, Kolacek, S, Mihatsch, W, Moreno, LA, Puntis, J, Shamir, R, Szajewska, H, Turck, D & Van Goudoever, J 2011, 'Supplementation of N-3 LCPUFA to the diet of children older than 2 years: A commentary by the ESPGHAN committee on nutrition', Journal of Pediatric Gastroenterology and Nutrition, vol. 53, no. 1, pp. 2-10. https://doi.org/10.1097/MPG.0b013e318216f009
Agostoni, Carlo ; Braegger, Christian ; Decsi, T. ; Kolacek, Sanja ; Mihatsch, Walter ; Moreno, Luis A. ; Puntis, John ; Shamir, Raanan ; Szajewska, Hania ; Turck, Dominique ; Van Goudoever, Johannes. / Supplementation of N-3 LCPUFA to the diet of children older than 2 years : A commentary by the ESPGHAN committee on nutrition. In: Journal of Pediatric Gastroenterology and Nutrition. 2011 ; Vol. 53, No. 1. pp. 2-10.
@article{50605059b32446ddbfe38ffed383906f,
title = "Supplementation of N-3 LCPUFA to the diet of children older than 2 years: A commentary by the ESPGHAN committee on nutrition",
abstract = "The aim of this commentary is to review data on the effect of supplementation of paediatric patients ages 2 years or older with n-3 long-chain polyunsaturated fatty acids (LCPUFA). Some evidence for a positive effect on functional outcome in children with attention-deficit/hyperactivity disorder (ADHD) was found; however, benefit was seen in only about half of the randomised controlled trials (RCT), and studies varied widely not only in dose and form of supplementation but also in the functional outcome parameter tested. The committee concludes that there are insufficient data to recommend n-3 LCPUFA supplementation in the treatment of children with ADHD, but further research on n-3 LCPUFA supplementation in ADHD may be worthwhile. The committee was unable to find evidence of a favourable effect of n-3 LCPUFA supplementation on cognitive function in children. Although no benefit of n-3 LCPUFA supplementation was seen for major clinical outcome parameters in children with cystic fibrosis, a potentially beneficial shift towards less-inflammatory eicosanoid profiles seen in 2 studies provides grounds for further investigation; it is possible that earlier and longer supplementation periods may be needed to demonstrate clinical effect. For children with phenylketonuria, the limited data available suggest that supplementation of n-3 LCPUFA to the diet is both feasible and safe, but offers only transient benefit in visual function. For children with bronchial asthma there are insufficient data to suggest that LCPUFA supplementation has a beneficial effect. The committee advises paediatricians that most health claims about supplementation of n-3 LCPUFA in various diseases in children and adolescents are not supported by convincing scientific data.",
keywords = "attention-deficit/hyperactivity disorder, commentary, cystic fibrosis, n-3 long-chain polyunsaturated fatty acids, phenylketonuria",
author = "Carlo Agostoni and Christian Braegger and T. Decsi and Sanja Kolacek and Walter Mihatsch and Moreno, {Luis A.} and John Puntis and Raanan Shamir and Hania Szajewska and Dominique Turck and {Van Goudoever}, Johannes",
year = "2011",
month = "7",
doi = "10.1097/MPG.0b013e318216f009",
language = "English",
volume = "53",
pages = "2--10",
journal = "Journal of Pediatric Gastroenterology and Nutrition",
issn = "0277-2116",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Supplementation of N-3 LCPUFA to the diet of children older than 2 years

T2 - A commentary by the ESPGHAN committee on nutrition

AU - Agostoni, Carlo

AU - Braegger, Christian

AU - Decsi, T.

AU - Kolacek, Sanja

AU - Mihatsch, Walter

AU - Moreno, Luis A.

AU - Puntis, John

AU - Shamir, Raanan

AU - Szajewska, Hania

AU - Turck, Dominique

AU - Van Goudoever, Johannes

PY - 2011/7

Y1 - 2011/7

N2 - The aim of this commentary is to review data on the effect of supplementation of paediatric patients ages 2 years or older with n-3 long-chain polyunsaturated fatty acids (LCPUFA). Some evidence for a positive effect on functional outcome in children with attention-deficit/hyperactivity disorder (ADHD) was found; however, benefit was seen in only about half of the randomised controlled trials (RCT), and studies varied widely not only in dose and form of supplementation but also in the functional outcome parameter tested. The committee concludes that there are insufficient data to recommend n-3 LCPUFA supplementation in the treatment of children with ADHD, but further research on n-3 LCPUFA supplementation in ADHD may be worthwhile. The committee was unable to find evidence of a favourable effect of n-3 LCPUFA supplementation on cognitive function in children. Although no benefit of n-3 LCPUFA supplementation was seen for major clinical outcome parameters in children with cystic fibrosis, a potentially beneficial shift towards less-inflammatory eicosanoid profiles seen in 2 studies provides grounds for further investigation; it is possible that earlier and longer supplementation periods may be needed to demonstrate clinical effect. For children with phenylketonuria, the limited data available suggest that supplementation of n-3 LCPUFA to the diet is both feasible and safe, but offers only transient benefit in visual function. For children with bronchial asthma there are insufficient data to suggest that LCPUFA supplementation has a beneficial effect. The committee advises paediatricians that most health claims about supplementation of n-3 LCPUFA in various diseases in children and adolescents are not supported by convincing scientific data.

AB - The aim of this commentary is to review data on the effect of supplementation of paediatric patients ages 2 years or older with n-3 long-chain polyunsaturated fatty acids (LCPUFA). Some evidence for a positive effect on functional outcome in children with attention-deficit/hyperactivity disorder (ADHD) was found; however, benefit was seen in only about half of the randomised controlled trials (RCT), and studies varied widely not only in dose and form of supplementation but also in the functional outcome parameter tested. The committee concludes that there are insufficient data to recommend n-3 LCPUFA supplementation in the treatment of children with ADHD, but further research on n-3 LCPUFA supplementation in ADHD may be worthwhile. The committee was unable to find evidence of a favourable effect of n-3 LCPUFA supplementation on cognitive function in children. Although no benefit of n-3 LCPUFA supplementation was seen for major clinical outcome parameters in children with cystic fibrosis, a potentially beneficial shift towards less-inflammatory eicosanoid profiles seen in 2 studies provides grounds for further investigation; it is possible that earlier and longer supplementation periods may be needed to demonstrate clinical effect. For children with phenylketonuria, the limited data available suggest that supplementation of n-3 LCPUFA to the diet is both feasible and safe, but offers only transient benefit in visual function. For children with bronchial asthma there are insufficient data to suggest that LCPUFA supplementation has a beneficial effect. The committee advises paediatricians that most health claims about supplementation of n-3 LCPUFA in various diseases in children and adolescents are not supported by convincing scientific data.

KW - attention-deficit/hyperactivity disorder

KW - commentary

KW - cystic fibrosis

KW - n-3 long-chain polyunsaturated fatty acids

KW - phenylketonuria

UR - http://www.scopus.com/inward/record.url?scp=79959833154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959833154&partnerID=8YFLogxK

U2 - 10.1097/MPG.0b013e318216f009

DO - 10.1097/MPG.0b013e318216f009

M3 - Article

VL - 53

SP - 2

EP - 10

JO - Journal of Pediatric Gastroenterology and Nutrition

JF - Journal of Pediatric Gastroenterology and Nutrition

SN - 0277-2116

IS - 1

ER -